Joseph S. Zakrzewski - 15 Dec 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Dec 2021
Net transactions value
+$39,844
Form type
4
Filing time
15 Dec 2021, 19:09:26 UTC
Previous filing
16 Dec 2021
Next filing
21 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Purchase $20,940 +2,000 +2.6% $10.47 79,267 15 Dec 2021 Direct F1, F2
transaction CYT Common Stock Purchase $18,904 +1,700 +2.1% $11.12 80,967 15 Dec 2021 Direct F2, F3
holding CYT Common Stock 58,671 15 Dec 2021 See Footnote F4
holding CYT Common Stock 149,051 15 Dec 2021 See Footnote F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.95 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $10.95 to $11.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4 Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F5 Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.